The Multi‐drug Polypill to Reduce Primary and Secondary Cardiovascular Events

The multi‐drug polypill to reduce primary and secondary cardiovascular events (CHD and stroke) , is mentioned in the text as a possible simple, safe and cheap preventive.
Early trials suggest it can improve compliance in patients already taking a number of
Its component drugs separately; and it is expected there will be results within a year
On whether it is effective in reducing blood pressure and serum cholesterol.It will
Take further years of follow‐up before definitive data on whether it reduces
Cardiovascular morbidity and mortality are available.Choose the best policy to
Implement now from among the following options:

A) License the polypill for general preventive use through doctors' prescriptions for at‐ risk patients who already take some or all the drugs in the pill
B) License the polypill for general preventive use through doctors' prescriptions for at‐ risk patients whether or not they currently take any of the drugs
C) Make the polypill freely available to the public from pharmacies without needing a doctor's prescription
D) Wait for the early results of the trials to see if patients levels of risk factors decrease
E) Wait until the longer‐term results of trials show a definitive lowering of CHD and stroke events and deaths, and the pill is approved by national drug oversight
Agencies such as the FDA